Research programme: Alzheimer's disease immunotherapeutics - Therapix Biosciences

Drug Profile

Research programme: Alzheimer's disease immunotherapeutics - Therapix Biosciences

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NasVax
  • Developer Therapix Biosciences
  • Class Alzheimer vaccines; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Israel
  • 13 Jan 2014 Therapix Biosciences responds to a letter from Ramot at Tel-Aviv University related to the licensing agreement for the BBS technology
  • 29 Jun 2011 Preclinical trials in Alzheimer's disease in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top